Apple receives a patent on pencil for non-touch surfaces

Apple receives a patent on pencil for non-touch surfaces

Apple has received a patent for a trackball tip- based pencil with optical sensors that enable writing on non-touch surfaces. The sensors track motion using light variations, allowing content creation without a screen. The technology uses optical flow and laser speckle sensors to detect movement, making the Pencil work on almost any surface. (Source – patentlyapple)

Huawei files a patent application for EV Battery with 3,000 km range

Huawei has filed a patent application for a solid-state EV battery that offers a 3000+ km range on a single charge. The battery features a nitrogen-doped sulfide electrolyte, boosting energy density to 400–500 Wh/kg, up to three times that of current lithium-ion batteries. Impressively, it can be fully charged in just 5 minutes. (Source – gaadiwaadi)

Geneticure Inc. receives a patent for genetic test to predict response in renal denervation for hypertension

Geneticure has received a patent for a genetic-based algorithm that predicts patient response to renal denervation. The method uses specific genetic markers and a weighted algorithm to assess treatment effectiveness. It helps physicians make personalized decisions beyond traditional risk assessments. (Source – businesswire)

Alpha Modus receives a patent for its AI retail technology

Alpha Modus has received a patent for real-time shopper engagement, digital signage, and autonomous retail optimization. The patent enhances the company’s position in AI-driven retail tech by bridging physical stores with intelligent decision engines. This issuance supports Alpha Modus’s expansion efforts amid growing enterprise demand. (Source – globenewswire)

Celcuity receives a patent patent for gedatolisib dosing regimen

Celcuity has received a patent for the clinical dosing regimen of its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients, extending exclusivity in the U.S. until 2042. Gedatolisib is a pan-PI3K and mTORC1/2 inhibitor targeting the PI3K/AKT/mTOR pathway, with ongoing phase 3 trials underway. (Source – in.investing)

Avalon GloboCare receives a patent for novel CAR-T and CAR-NK cell technology in Hong Kong

Avalon GloboCare has received a patent for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology. The patent strengthens Avalon’s global intellectual property strategy and provides long-term protection for the company’s innovations in the Hong Kong Special Administrative Region. (Source – globenewswire)

PostProcess Technologies receives 50th patent in additive manufacturing

PostProcess Technologies has received its 50th patent, marking a major milestone in its mission to automate and scale post-printing in additive manufacturing. The patents cover innovations across hardware, software, and chemistry, including its flagship BASE and DEMI product lines. These solutions enable efficient, consistent support and resin removal at scale. (Source – voxelmatters)

Oryzon receives patent grant decisions in Canada and Israel for vafidemstat

Oryzon Genomics has received “Decision to grant” communications from Canada and Israel for patents covering the use of vafidemstat to treat aggression and social withdrawal. These symptoms are linked to various CNS disorders, and vafidemstat is currently in or planned for multiple Phase II and III clinical trials. (Source – finance.yahoo)